Ovagen
Also known as: Peptídeo hepático e gastrointestinal
Molecular Identifiers
Overview
Liver and gastrointestinal tract bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in hepatocytes and the digestive epithelium. Marketed in Russian pharmacies as oral capsules for hepatogastrointestinal support in short cycles.
Ovagen is presented as a short hepatogastrointestinal axis bioregulator, acting on hepatocytes and GI epithelium, with proposed normalization of digestive mucosa cell renewal and liver function. It belongs to the family of short Khavinson-type tripeptides, designed to act via epigenetic regulation of gene expression in specific tissues.
It has no regulatory approval from the FDA, EMA, or ANVISA. The product is marketed in Russian pharmacies as oral capsules in typical cycles of 10–30 days repeated every 4–6 months. In other markets it is dispensed by compounding pharmacies as off-label use. Most evidence is still preclinical and originates from researcher Vladimir Khavinson's group in Saint Petersburg.
Within the Khavinson family, Ovagen is often compared to Livagen on the hepato-gastrointestinal axis: while Livagen (the Lys-Glu-Asp-Ala tetrapeptide) is described with a tighter focus on the hepatocyte, Ovagen (the Glu-Asp-Leu tripeptide) is presented as extending the action toward the digestive epithelium and intestinal mucosa cell renewal. All of this comparative literature is largely Russian and preclinical.
EDL Glu-Asp-Leu Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in hepatocytes
- Modulation of cell renewal in gastrointestinal epithelium
- Normalization of digestive tract mucosa
- Support for liver function and detoxification
- Bioregulatory effect on the hepatogastrointestinal axis
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing hepato/gastrointestinal peptide complex) |
| Frequency | 1-2 times daily, with meals |
| Timing | With meals |
| Duration | 10-30 days per cycle, repeat the course every 4-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Ovagen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Ovagen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals